Monte Rosa Therapeutics, Inc. (GLUE)
NASDAQ$5.45-0.22 (-3.88%)
Market Cap
$348.35M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
323 of 919
Rank in Industry
190 of 523
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
GLUE Insider Trading Activity
GLUE Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $58,383 | 1 | 11 |
Sells | $12,302,077 | 8 | 89 |
Related Transactions
| Leo Chandra P. | director | 1 | $58,383 | 0 | $0 | $58,383 |
| Dunn Edmund | Principal Accounting Officer | 0 | $0 | 2 | $11,042 | $-11,042 |
| Versant Venture Capital VI, L.P. | 10 percent owner | 0 | $0 | 6 | $12.29M | $-12.29M |
About Monte Rosa Therapeutics, Inc.
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Insider Activity of Monte Rosa Therapeutics, Inc.
Over the last 12 months, insiders at Monte Rosa Therapeutics, Inc. have bought $58,383 and sold $12.3M worth of Monte Rosa Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Monte Rosa Therapeutics, Inc. have bought $138.4M and sold $12.3M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Leo Chandra P. (director) — $58,383.
The last purchase of 10,000 shares for transaction amount of $58,383 was made by Leo Chandra P. (director) on 2025‑03‑24.
List of Insider Buy and Sell Transactions, Monte Rosa Therapeutics, Inc.
| 2025-03-24 | Leo Chandra P. | director | 10,000 0.0163% | $5.84 | $58,383 | -2.88% | ||
| 2024-10-29 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 67,905 0.1081% | $9.16 | $621,801 | -27.64% | |
| 2024-10-28 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 89,990 0.2667% | $9.66 | $869,240 | -28.16% | |
| 2024-09-20 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 1.13M 1.8595% | $6.53 | $7.4M | +0.62% | |
| 2024-09-13 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 9,269 0.0153% | $6.16 | $57,100 | +6.83% | |
| 2024-09-12 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 16,047 0.0263% | $6.00 | $96,309 | +8.85% | |
| 2024-09-11 | Sale | Versant Venture Capital VI, L.P. | 10 percent owner | 541,897 0.833% | $6.00 | $3.25M | +4.18% | |
| 2024-07-05 | Sale | Dunn Edmund | Principal Accounting Officer | 1,610 0.0027% | $3.83 | $6,166 | +65.52% | |
| 2024-06-03 | Sale | Dunn Edmund | Principal Accounting Officer | 1,207 0.002% | $4.04 | $4,876 | +46.73% | |
| 2021-06-28 | Yang Rick | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | ||
| 2021-06-28 | Walker Paul Edward | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | ||
| 2021-06-28 | Sonsini Peter W. | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | ||
| 2021-06-28 | SANDELL SCOTT D | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | ||
| 2021-06-28 | New Enterprise Associates 17, L.P. | director | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | ||
| 2021-06-28 | Mathers Edward T | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | ||
| 2021-06-28 | MAKOWER JOSHUA | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | ||
| 2021-06-28 | Makhzoumi Mohamad | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | ||
| 2021-06-28 | Landsman Liza | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | ||
| 2021-06-28 | Florence Anthony A. Jr. | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% | ||
| 2021-06-28 | Chang Carmen | 10 percent owner | 1.05M 20.5778% | $19.00 | $19.95M | -7.95% |
Total: 25
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Versant Venture Capital VI, L.P. | 10 percent owner | 1573453 2.5611% | $8.92M | 1 | 6 | <0.0001% |
| Dunn Edmund | Principal Accounting Officer | 13944 0.0227% | $79,062.48 | 0 | 2 | |
| Leo Chandra P. | director | 10000 0.0163% | $56,700.00 | 1 | 0 | |
| MAKOWER JOSHUA | 10 percent owner | 7692298 12.5207% | $43.62M | 1 | 0 | <0.0001% |
| SANDELL SCOTT D | 10 percent owner | 7692298 12.5207% | $43.62M | 1 | 0 | <0.0001% |
| BASKETT FOREST | 10 percent owner | 7692298 12.5207% | $43.62M | 1 | 0 | <0.0001% |
| Mathers Edward T | 10 percent owner | 7692298 12.5207% | $43.62M | 1 | 0 | <0.0001% |
| Walker Paul Edward | 10 percent owner | 7692298 12.5207% | $43.62M | 1 | 0 | <0.0001% |
| Sonsini Peter W. | 10 percent owner | 7692298 12.5207% | $43.62M | 1 | 0 | <0.0001% |
| Florence Anthony A. Jr. | 10 percent owner | 7692298 12.5207% | $43.62M | 1 | 0 | <0.0001% |
| Behbahani Ali | 7692298 12.5207% | $43.62M | 1 | 0 | <0.0001% | |
| Landsman Liza | 10 percent owner | 7692298 12.5207% | $43.62M | 1 | 0 | <0.0001% |
| Makhzoumi Mohamad | 10 percent owner | 7692298 12.5207% | $43.62M | 1 | 0 | <0.0001% |
| Chang Carmen | 10 percent owner | 7692298 12.5207% | $43.62M | 1 | 0 | <0.0001% |
| New Enterprise Associates 17, L.P. | director | 7692298 12.5207% | $43.62M | 1 | 0 | <0.0001% |
| Yang Rick | 10 percent owner | 7692298 12.5207% | $43.62M | 1 | 0 | <0.0001% |
| Cormorant Asset Management, LP | 3202200 5.2122% | $18.16M | 1 | 0 | <0.0001% | |
| Bolzon Bradley J PhD | 2097938 3.4148% | $11.9M | 1 | 0 | <0.0001% |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$109,415,500 | 33 | 18.13% | $357.98M | |
$41,446,394 | 27 | 12.91% | $299.38M | |
$73,300,822 | 22 | 51.91% | $382.53M | |
$24,857,912 | 21 | -35.40% | $304.57M | |
$14,865,077 | 18 | -28.56% | $388.28M | |
Monte Rosa Therapeutics, Inc. (GLUE) | $276,750,010 | 16 | -7.95% | $348.35M |
$46,442,839 | 15 | -20.05% | $369.92M | |
$3,287,638 | 15 | -0.23% | $368.47M | |
$7,254,955 | 14 | 20.70% | $337.79M | |
$18,945,106 | 14 | -27.94% | $362.85M | |
$1,037,470 | 13 | 78.00% | $346.32M | |
$65,355,913 | 13 | -3.42% | $353.66M | |
$52,263,118 | 10 | -6.89% | $347.62M | |
$49,621,830 | 8 | 9.29% | $334.92M | |
$4,706,376 | 8 | 42.30% | $330.4M | |
$51,588,185 | 5 | 19.18% | $352.71M | |
$79,238,118 | 4 | -26.47% | $342.67M | |
$602,180 | 4 | -26.17% | $383.3M | |
$8 | 2 | 28.83% | $344.03M |
GLUE Institutional Investors: Active Positions
| Increased Positions | 71 | +98.61% | 16M | +32.32% |
| Decreased Positions | 28 | -38.89% | 4M | -9.08% |
| New Positions | 35 | New | 10M | New |
| Sold Out Positions | 11 | Sold Out | 788,315 | Sold Out |
| Total Postitions | 115 | +59.72% | 59M | +23.23% |
GLUE Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Nea Management Company, Llc | $44,615.00 | 12.41% | 7.69M | 0 | 0% | 2024-12-31 |
| Price T Rowe Associates Inc /Md/ | $41,276.00 | 11.48% | 7.12M | +515,496 | +7.81% | 2024-12-31 |
| Versant Venture Management, Llc | $32,787.00 | 9.12% | 5.65M | +6M | New | 2024-12-31 |
| Fmr Llc | $32,181.00 | 8.95% | 5.55M | +447,035 | +8.76% | 2024-12-31 |
| Baker Bros. Advisors Lp | $28,513.00 | 7.93% | 4.92M | 0 | 0% | 2024-12-31 |
| Avoro Capital Advisors Llc | $25,201.00 | 7.01% | 4.34M | -1M | -24.96% | 2024-12-31 |
| Blackrock, Inc. | $22,273.00 | 6.19% | 3.84M | +938,673 | +32.35% | 2024-12-31 |
| Vanguard Group Inc | $18,307.00 | 5.09% | 3.16M | +622,134 | +24.55% | 2024-12-31 |
| Bvf Inc/Il | $16,034.00 | 4.46% | 2.76M | +3M | New | 2024-12-31 |
| Morgan Stanley | $13,081.00 | 3.64% | 2.26M | +2M | +1,699.5% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
No data is available at this moment.
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.